Publications and Abstracts

Select Publications

Kopparthy P, Murphy MDC. Rapid and Durable Response With Nab-Sirolimus After Everolimus Failure in a Patient With Perivascular Epithelioid Cell Tumors (PEComas) of the Uterus. Cureus 2021;13(5):e14951

Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: Final results of a phase I trial. Clin Cancer Res 2013;19(19):5474-5484

AMPECT Registration Study Presentations

Wagner A, Ravi V, Ganjoo KN, Van Tine BA, et al. Long-term follow-up from AMPECT, an open-label phase 2 registration trial of nab-sirolimus for patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Oral Presentation at CTOS November 2020, Virtual (Abst #3463014)

Wagner A, Ravi V, Ganjoo KN, Van Tine BA, et al. Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT. Poster discussion at ASCO June 2020, Virtual (Abst #11516JCO 2020 38, no. 15_suppl

Dickson MA,  Ravi V, Ganjoo KN, et al. Weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): results from AMPECT, an open-label phase 2 registration trial with independent radiology review. Oral presentation at CTOS November 2019, Tokyo, Japan (Abst #3206452)

Wagner A, Dickson MA, Ravi V, et al. Mutational and biomarker correlative analysis of mTOR pathway aberrations in patients with advanced malignant perivascular epithelioid cell tumors (PEComa) treated with nab-sirolimus: results from AMPECT, an open-label phase 2 registrational trial. Poster presentation at CTOS November 2019, Tokyo, Japan (Abst #3258096)

Wagner A, Ravi V, Ganjoo KN, et al. ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase 2 Registration Trial. Oral presentation at ASCO June 2019, Chicago, IL (Abst #11005JCO 2019 37, no. 15_suppl

Select Presentations: Expanded Access Program and Other Clinical Trials

Dickson MA, Ravi V, Ganjoo K et al. Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations. Poster presentation at ASCO 2021, Virtual (Abst # 339405)

Simon M, Gomberg-Maitland M, Oudiz RJ, e al. Patients with severe pulmonary arterial hypertension treated with ABI-009, nab-sirolimus, an mTOR inhibitor: Interim results from a phase 1 clinical trial. Poster presentation at ACC 2019, New Orleans, LA (Abst #1242-482 * Best Poster Award* J Am Clin Cardiol 2019 Vol 73, Issue 9 Suppl 1

Simon M, Gomberg-Maitland M, Oudiz RJ, et al. ABI-009, nab-sirolimus, an mTOR inhibitor with high lung accumulation in preclinical models is active in patients with severe pulmonary arterial hypertension. Poster presentation at ATS 2019, Orlando, FL (Abst #A4409Am J Resp Critical Care Med 2019;199:A4409

Select Preclinical Presentations

Hou S, Du H, Schmid A, Kwiatkowski D, Desai N. nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts. Poster Presentation at AACR-NCI-EORTC 2021, Virtual International Conference on Molecular Targets and Cancer Therapeutics (P138)

Hou S, Schmid A, Desai N. ABI-009 (nab-sirolimus) improves tumor accumulation and antitumor activity over oral mTOR inhibitors. Poster Presentation at AACR 2019, Atlanta, GA (Abst#348Cancer Res 2019, Vol 79 (13)

Hou S, Schmid A, Desai N. Distinct pharmacokinetics, tissue distribution and CNS penetration of ABI-009 (nab-sirolimus). Poster Presentation at AACR 2019, Atlanta, GA (Abst#3896Cancer Res 2019, Vol 79 (13)